ArticleChemistry & biodiversity2026
In Vitro and In Silico Studies on Unique Key Components of Hypericum Species, Focusing on Their Role in Inhibiting Enzymatic Pathways.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated Phytochemical Profiling, In Vitro Bioactivity, Molecular Docking, and Pharmacokinetic-Toxicity Evaluation ofLife (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
An ever-increasing number of ailments are being treated using Hypericum L. species, which are gaining both popular and scientific relevance. This study set out to thoroughly examine the chemical and biological aspects of ethanol extracts from the roots and aerial parts of the Hypericum empetrifolium subsp. empetrifolium Willd., Hypericum triquetrifolium Turra, and Hypericum pruinatum Boiss. Et. Honey species. Thus, it is aimed to shed light on the uses of Hypericum species among the public by revealing both their chemical and biological profiles. Species-specific phenolic content of the samples was determined by LC-MS/MS. In addition, antioxidant, anticholinesterase, urease, tyrosinase, elastase, collagenase, and angiotensin I-converting enzyme (ACE) inhibition activities of the extracts and some major components (chlorogenic acid, hesperidin, hyperoside, quercitrin, quercetin, pseudohypericin, hypericin) specific to Hypericum species were determined. LC-MS/MS results showed that some samples were rich in hyperoside (49 365.6 µg analyte/g extract), hesperidin (10 077.8), chlorogenic acid (15 027.8), luteolin-7-glycoside (1629.6), quercitrin (6979.7), pseudohypericin (998.8), and hypericin (386.5). The samples were found to have a high potential in CUPRAC, DPPH, and ABTS antioxidant methods. High enzyme activity was seen in particular for acetylcholinesterase (AChE) (inhibition%: 54.00 ± 0.97) H. pruinatum root ethanol extract, for butyrylcholinesterase (BChE) (inhibition%: 73.33 ± 1.49) of H. triquetrifolium aerial part ethanol extract, for urease (inhibition%: 49.20 ± 1.27) of H. empetrifolium subsp. empetrifolium aerial part ethanol extract, for tyrosinase (inhibition%: 55.40 ± 0.52) of H. pruinatum root ethanol extract, and elastase (inhibition%: 36.84 ± 0.45) of H. pruinatum aerial part ethanol extract. The enzyme inhibitory potentials of hesperidin (urease inhibition%: 54.32 ± 1.35, tyrosinase: 73.87 ± 2.06, elastase: 82.23 ± 1.41, collagenase: 67.37 ± 0.73, and ACE: 80.74 ± 0.85) and quercetin (AChE inhibition%: 57.82 ± 1.21, BChE: 92.82 ± 1.84, urease: 73.17 ± 1.79, tyrosinase: 65.25 ± 1.73, elastase: 98.04 ± 2.28, and ACE: 86.74 ± 0.85), principal constituents of Hypericum species, were shown to be significantly high on the basis of both in vitro and in silico analyses. The in vitro and in silico test findings of Hypericum species and their principal components indicate that they are promising sources of natural agents, suggesting their potential application in the food and pharmaceutical industries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.